Opendata, web and dolomites

N-IF SIGNED

The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 N-IF project word cloud

Explore the words cloud of the N-IF project. It provides you a very rough idea of what is the project "N-IF" about.

ultimate    experimental    induce    disease    population    preceded    animals    hampered    clients    chronic    founded    fibrotic    protocols    reproducibility    efficacy    proprietary    doors    eliminates    science    health    exhibits    feasibility    tests    mouse    liver    robustness    lack    renal    segments    enlarging    bio    develops    company    inflammation    50    drugs    validation    consuming    nash    humans    decrease    25    100    time    date    prevalence    preclinical    industry    inflammatory    experiment    diseases    therapies    good    models    commercializing    reductions    2015    prepare    pipeline    drug    inficure    animal    pathology    anti    model    progression    shorten    minimize    huge    resemble    intensive    swedish    primary    acquired    pharmaceutical    market    labour    validated    spontaneously    mice    fibrosis    efficient    life    opening    demanded    translate    despite    technically    human    pulmonary    world    course    weeks    conduct   

Project "N-IF" data sheet

The following table provides information about the project.

Coordinator
INFICURE BIO AKTIEBOLAG 

Organization address
address: TVISTEVAGEN 48C
city: UMEA
postcode: 907 36
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.inficurebio.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2018-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INFICURE BIO AKTIEBOLAG SE (UMEA) coordinator 50˙000.00

Map

 Project objective

InfiCure Bio is a Swedish Life Science company that was founded in 2015 with the primary objective of developing and commercializing a proprietary model for preclinical efficacy testing of anti-inflammatory and anti-fibrotic drugs. Our key product, the N-IF mouse, is a unique animal model that spontaneously develops fibrosis which is preceded by chronic inflammation and exhibits the same course of fibrotic disease progression as in humans, a unique feature that has been an ultimate need demanded by the pharmaceutical industry for many years.

There are no efficient therapies aimed against fibrotic diseases despite the high prevalence among the world population and the huge impact on human health. To date, drug development has been hampered due to the lack of good and reliable preclinical models that better resemble human fibrotic disease conditions. The N-IF mouse eliminates the problems of currently available animal models that are time-consuming, labour-intensive to induce fibrosis and have a low reproducibility. Its unique features will allow to shorten test protocols by 4-8 weeks, increase robustness of tests due to its 100% reproducibility and minimize the number of experimental animals needed. Reductions in experiment time and in mice numbers directly translate into a 25 - 50% decrease in the overall costs of preclinical testing of anti-fibrotic drugs. We have already technically validated the N-IF mouse as a model for liver fibrosis and have acquired two clients. The objective of the Phase 1 project is to conduct a feasibility study and prepare for further validation studies of the mouse model in order to establish the pathology of NASH, renal and pulmonary fibrosis that will be conducted as part of Phase 2, enlarging our pipeline models for fibrotic diseases and opening doors to new segments of the fibrotic diseases market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "N-IF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "N-IF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More